Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $33807 | $8M | $29M | — | — | — |
| Enterprise Value | $10M | $18M | $42M | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — |
| P/S Ratio | 0.00 | 0.13 | 0.45 | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | 5.82 | — | — | — |
| P/OCF | — | — | 5.59 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.29 | 0.65 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | 8.36 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 51.2% | 51.2% | 46.2% | 62.8% | 50.5% | 59.4% |
| Operating Margin | -7.7% | -7.7% | -4.1% | -0.4% | -21.3% | -22.2% |
| Net Profit Margin | -13.8% | -13.8% | -13.1% | -4.3% | -24.6% | -22.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — |
| ROA | -27.8% | -27.8% | -23.6% | -6.8% | -33.1% | -28.0% |
| ROIC | — | — | — | — | — | — |
| ROCE | — | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | 2.55 | 2.11 | — | — |
| Interest Coverage | -15.34 | -15.34 | -3.77 | -0.28 | -20.23 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.49 | 0.49 | 0.60 | 0.52 | 0.52 | 0.78 |
| Quick Ratio | 0.33 | 0.33 | 0.43 | 0.33 | 0.42 | 0.54 |
| Cash Ratio | 0.05 | 0.05 | 0.07 | 0.07 | 0.07 | 0.07 |
| Asset Turnover | — | 2.35 | 1.80 | 1.54 | 1.44 | 1.23 |
| Inventory Turnover | 4.35 | 4.35 | 4.43 | 2.48 | 5.06 | 1.81 |
| Days Sales Outstanding | — | 18.86 | 65.22 | 38.70 | 104.53 | 117.64 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | 17.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $1M | $1M | $1M | $1M | $1M |
Liquidity and capital exhaustion
As reported in recent financial statements, DHAI's operating margin has deteriorated to -25.4% in 2025Q4, reflecting a persistent inability to leverage its fixed cost base against a shrinking revenue profile, which warrants significant caution regarding the company's path toward achieving sustainable, positive operating profitability.
The decline in gross margin from 59.4% in 2023Q4 to 45.8% in 2025Q4 suggests that the company is facing mounting pricing pressure or rising input costs that it cannot pass on to its hospital customers. This margin compression, combined with negative operating margins, implies that the current business model lacks the necessary scale to absorb the high R&D and regulatory overhead inherent in the medical robotics sector.
Based on the provided quarterly data, DHAI's cash conversion cycle has expanded significantly to 290 days in 2025Q4, driven by elevated days inventory outstanding of 375 days, which suggests that the company is struggling to convert its robotic hardware inventory into cash in a timely manner.
The prolonged cash conversion cycle indicates a structural bottleneck in the company's ability to manage its working capital effectively. Investors should monitor the high inventory levels, as they may signal either a buildup of obsolete robotic units or a failure to align production schedules with the current, more sluggish hospital procurement environment.
According to the most recent balance sheet filings, DHAI's current ratio has fallen to 0.49, a level that indicates the company lacks sufficient liquid assets to cover its short-term liabilities, thereby increasing the risk of a liquidity crisis in the absence of immediate external financing.
The quick ratio of 0.33 further underscores the company's reliance on inventory liquidation to meet obligations, which is a high-risk strategy given the current contraction in revenue. This liquidity profile suggests that the firm is operating with virtually no margin for error, making it highly vulnerable to any further delays in customer payments or unexpected operational expenses.
Market participants often misapply price-to-sales multiples to DHAI, which obscures the company's underlying cash burn and negative equity position, failing to account for the fact that revenue growth is currently contracting rather than providing a reliable foundation for future earnings expansion or valuation support.
Using P/S multiples for a company with negative net margins and a deteriorating balance sheet is misleading, as it ignores the capital intensity required to sustain operations. A more appropriate analytical framework would focus on the cash burn rate relative to the remaining cash runway, as this provides a clearer picture of the company's immediate survival risk compared to traditional valuation metrics.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DHAI stock.
DIH Holding US, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, DIH Holding US, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
DIH Holding US, Inc. has 51.2% gross margin and -7.7% operating margin.